1. ����ʡ����ҽԺ
2. ����ʡ����ҽԺƤ����

��״������һ����DZ���ڼ������񾭽ڻ����񾭵ĸо��񾭽��е�ˮ��-��״������ټ�������µ�Ƥ�������䷢����ˮ��-��״����������Ե�ϸ�����߹����½��йء�Ϊ��Σ��Ⱥ����ˮ��-��״�����������ϸ�����ߵĴ�״�������磬������Ч�Ľ��ʹ�״����ķ����ʺͼ��������س̶ȡ���״�������Ӧ����Ӧ�ÿ�����ҩ�Ｐ���ʵ�ֹʹ���������⻼�ߵ��ٴ�֢״����Ԥ��������ʹ�ķ�����ͨ���Դ�״�����Tϸ�����߻��Ƶ������о���Ϊ���������ṩ�������ݡ�

Herpes zoster is a skin disease caused by the reactivation of latent varicella zoster virus��VZV�� in the posterior root ganglia of spinal nerves or sensory ganglia of cranial nerves. It is associated with a decline in VZV?۲specific cell-mediated immunity. To boost VZV-specific cell-mediated immunity via immunizing with VZV-targeted vaccines may reduce the incidence and severity of herpes zoster in high-risk populations. Once herpes zoster develops, antivirals and appropriate analgesics should be administrated as early as possible to relieve symptoms and prevent the development of post-herpetic neuralgia. Further research into the mechanisms of T lymphocyte-mediated immunity in herpes zoster may provide a solid theoretical basis for the immunotherapy of herpes zoster.

[�ο�����] [1]WEINBERG JM. Herpes zoster: epidemiology, natural history, and common complications[J]. J Am Acad Dermatol,2007,57(6 Suppl):S130-135. [2]Won Suk Choi,Ji Yun Noh,Joong Yeon Huh,et al.Disease Burden of herpes zoster in Korea[J].J Clin Virol,2010,47:325-329. [3]Vossen MT,Gent MR,Weel JF,et al. Development of virus-specific CD4+T cells on reexposure to varicella-zoster virus[J]. J Infect Dis,2004,190(1): 72-78. [4]Arvin A.Aging,immunity,and the varicella-zoster virus[J]. N Engl J Med, 2005,352:2266-2267. [5]Thomas SL,Hall AJ.What does epidemiology tell us about risk factors for herpes zoster[J].Lancet Infect Dis,2004,4:26–33. Johnson R,McElhaney J,Pedalino B,Levin M.Prevention of herpes zoster and its painful and debilitating complications[J].Int J Infect Dis,2007,11(S2):S43–8. [6]Aspinall R.Age-related changes in the function of T cells[J].Microsc Res Tech,2003,62:508-513. [7]Svahn A,Linde A,Thorstensson R,et al.Development and evaluation of a flow-cytometric assay of specific cell-mediated immune response in activated whole blood for the detection of cell-mediated immunity against varicella-zoster virus[J].Journal of Immunological Methods,2003,277(1):17-25. [8]HAYWARD AR. In vitro measurement of humanT cell responses to varicella zoster virus antigen[J]. Arch Virol ,2001, 17(Suppl 1):143-149. [9]Higa K,Noda B,Manabe H,et al.T-lymphocyte subsets in otherwise healthy patients with herpes zoster and relationships to the duration of acute herpetic pain[J].Pain,1992,51:111-118. [10]Cohen JL.Strategies for Herpes zoster vaccination of immunocompromised patients[J].J Infect Dis,2008,197:S237–41. [11]Dong C, Flavellr A. Th1 andTh2 cells[J].Curr Opin Hematol,2001, 8(1): 47-51. [12]Asanuma H,Sharp M,Maecker HT,et al.Frequencies of memoty T cells specific for varicella-zoster virus,herpes simplex virus,and cytomegalovirus by intracellular detection of cytokine expression[J].J Infect Dis,2000,181(3):859-66. [13]������,��,������.��״�����Ѫ��Thϸ�����ӵļ��[J].�й�Ƥ���Բ�ѧ��־,2008,22(12):721-725. [14]Daisuke Suzuki,Katsunori Furukawa,Fumio Kimura,et al.Effects of peri-operative immunonutrition on cell-mediated immunity,T helper type 1(Th1)/Th2 differentiation,and Th17 response after pancreaticoduodenectomy[J].Surgery,2010,1:1-9. [15]Vagvala SP,Thebeau LG,Wilson SR,et al.Virus-encoded B7.2 costimulation molecules enhance the protective capacity of a replication-defective herpes simplex virus type 2 vaccine in immunocompetent mice[J].J Virol,2009,83:953-960. [16]Nightingale ZD,Patkar C,Rothman AL,et al.Viral replication and paracrine effects result in distinct,functional responses of dendritic cells following infection with dengue 2 virus[J].J Leukoc Biol,2008,84:1028-1038. [17]Kaufmann,D.E.,Kavanagh,D.G.,Pereyra,F.,et al.Upregulation of CTLA-4 by HIV-specific CD4+T cells correlates with disease progression and defines a reversible immune dysfunction[J].Nat Immunol,2007,8,1246-1254. [18]Morrow G,Slobedman B,Cunningham AL,et al.Varicella-zoster virus productively infects mature dendritic cells and alters their immune function[J].J Virol,2003,77:4950-4959. [19]�վ꣬��溣����ӵ�.�������Ƶ���c-FLIP�ڴ�״�����ϸ�����������õ��о�[J].�й�Ƥ���Բ�ѧ��־,2008,22(4):207-210. [20]Peng-jun Lu,Gary L.Euler,Aisha O.Junaan,Rafael Harpaz.Herpes zoster vaccination among adults aged 60 years or older in the United States,2007:Uptake of the first new vaccine to target seniors[J].Vaccine,2009,27:882-887. [21] Opstelten W,Eekhof J,Knuistingh Neven A,Verheij T.Treatment of herpes zoster[J].Can Fam Physician,2008,54:373–7. [22]Kenneth E.Schmader,Robert H.Dworkin.Natural History and Treatment of Herpes zoster[J].The Journal of Pain,2008,9(1,Suppl 1):S3-9. [23]Young L.Post-herpetic neuralgia:a review of advances in treatment and prevention[J].J Drugs Dermatol,2006,5:938–41. [24]Schmader KE,Dworkin RH.Natural history and treatment of herpes zoster[J].J Pain, 2008,9(S1):S3–9. [25]Metzner B,Gruneisl R,Gebauer W.Late infectious complications after high-dose therapy and autologous blood stem cell transplantation[J].Med Klin,2002,97(11):650-658. [26]������,�ߺ鲨,�������.���������ϸ�����Τ���ƴ�״������Ч�۲�[J].�й�����ѧ��־,2009,9(8):1798. [27]S. Estrada-Parra, A.Nagaya, E.Serrano,et al.Comparative study of transfer factor and acyclovir in the treatment of herpes zoster[J].International Journal of Immunopharmacology,1998,20:521-535. [28]Warnatz K,Draeger R,Schlesier M,et al.Successful IL-2 therapy for relapsing herpes zoster infection in a patient with idiopathic CD4+T lymphocytopenia[J]. Immunobiology,2000,202(2):204-211.